| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a71caf66bd467412cc746f6147db0025 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2020-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_457c8a7bf89b28863d4a004bbe5dc879
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_856803cd1ee88ac7413a9383fcb6f425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7e1b6008b0f30a8368480602981c63c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5a58ee7ea59ed96708cab2d5c5c7e03 |
| publicationDate |
2021-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021113661-A1 |
| titleOfInvention |
Amorphous and polymorphic form of a specific chk1 inhibitor |
| abstract |
The invention relates to solid state forms, including amorphous and crystalline forms, of the CHK1 inhibitor compound 5-((5-(4-(4-fluoro-1-methylpiperidin-4-yl)-2-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile and methods of preparing specific amorphous and polymorphic forms of the compound. |
| priorityDate |
2019-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |